Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Marek

Showing results (91-100 of 144) with videos related to

Pageof 15
Sort By:
The Lancet. Neurology|June 16, 2016
The new definition and diagnostic criteria of Parkinson's diseaseRonald B Postuma, Daniela Berg, Charles H Adler, et al.
Nature Medicine|October 8, 2024
Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trialGennaro Pagano, Annabelle Monnet, Adriana Reyes, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 17, 2015
MDS clinical diagnostic criteria for Parkinson's diseaseRonald B Postuma, Daniela Berg, Matthew Stern, et al.
Annals of Clinical and Translational Neurology|March 11, 2026
Five-Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's DiseasePaulina Gonzalez-Latapi, Caroline Gochanour, Seung Ho Choi, et al.
Parkinsonism & Related Disorders|January 11, 2025
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline dataTania Nikolcheva, Gennaro Pagano, Nathalie Pross, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 30, 2025
Neuronal α-Synuclein Disease Stage Progression over 5 YearsTanya Simuni, Caroline Gochanour, Anuprita R Nair, et al.
Annals of Neurology|April 22, 2026
Developing a Virtual Research Environment in the Parkinson's Progression Markers Initiative: myPPMICraig E Stanley, Kimberly Fabrizio, Bridget A McMahon, et al.
Journal of Parkinson'S Disease|January 21, 2020
Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In PersonLana M Chahine, Iris Chin, Chelsea Caspell-Garcia, et al.
Lancet (London, England)|May 28, 2026
Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled studyTania Nikolcheva, Gennaro Pagano, Judith Anzures-Cabrera, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 17, 2015
MDS research criteria for prodromal Parkinson's diseaseDaniela Berg, Ronald B Postuma, Charles H Adler, et al.
Pageof 15

Showing results (91-100 of 144) with videos related to

Sort By:
Pageof 15
The Lancet. Neurology|June 16, 2016
The new definition and diagnostic criteria of Parkinson's diseaseRonald B Postuma, Daniela Berg, Charles H Adler, et al.
Nature Medicine|October 8, 2024
Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trialGennaro Pagano, Annabelle Monnet, Adriana Reyes, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 17, 2015
MDS clinical diagnostic criteria for Parkinson's diseaseRonald B Postuma, Daniela Berg, Matthew Stern, et al.
Annals of Clinical and Translational Neurology|March 11, 2026
Five-Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's DiseasePaulina Gonzalez-Latapi, Caroline Gochanour, Seung Ho Choi, et al.
Parkinsonism & Related Disorders|January 11, 2025
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline dataTania Nikolcheva, Gennaro Pagano, Nathalie Pross, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 30, 2025
Neuronal α-Synuclein Disease Stage Progression over 5 YearsTanya Simuni, Caroline Gochanour, Anuprita R Nair, et al.
Annals of Neurology|April 22, 2026
Developing a Virtual Research Environment in the Parkinson's Progression Markers Initiative: myPPMICraig E Stanley, Kimberly Fabrizio, Bridget A McMahon, et al.
Journal of Parkinson'S Disease|January 21, 2020
Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In PersonLana M Chahine, Iris Chin, Chelsea Caspell-Garcia, et al.
Lancet (London, England)|May 28, 2026
Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled studyTania Nikolcheva, Gennaro Pagano, Judith Anzures-Cabrera, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 17, 2015
MDS research criteria for prodromal Parkinson's diseaseDaniela Berg, Ronald B Postuma, Charles H Adler, et al.
Pageof 15